The Private Health Insurance Legislation Amendment Rules (No. 2) 2022 (the Amendment Rules No. 2) make consequential changes to the Private Health Insurance Rules to reflect the introduction of two new MBS items to treat chronic graft versus host disease (cGVHD) with integrated, closed-system, extracorporeal photopheresis (ECP) in conjunction with the drug methoxalen (on the Pharmaceutical Benefits Scheme), commencing 1 March 2022.
These Amendment Rules are in addition to the Private Health Insurance Legislation Amendment Rules (No. 1) 2022 which covered changes including pain management, anaesthesia, gynaecological and Participating Midwives services as well as amendments to the General Medical Services Table that made consequential changes to the Private Health Insurance Rules to reflect other changes to the MBS commencing 1 March 2022.
The Amendment Rules No. 2 were registered on the Federal Register of Legislation commence on 1 March 2022.
The Amendments add items 13761, and 13762 to:
- Schedule 6 of the Private Health Insurance (Complying Product) Rules 2015 for the purpose of describing hospital treatment(s) that must be covered under insurance policies, to categorise the two new MBS items into the Common treatments list; and,
- Schedule 3 of the Private Health Insurance (Benefit Requirements) Rules 2011 for the purpose of specifying minimum hospital accommodation benefit requirements, to classify the two new MBS items as Procedure-type B Non-Band Specific.
Further details on the Amendment Rules are included in the Explanatory Statement accompanying the Amendment Rules available on the Federal Register of Legislation or by searching ‘Private Health Insurance Legislation Amendment Rules (No. 2) 2022’.
Information and spreadsheets for MBS items assigned to a clinical category or procedure type are available at Private health insurance clinical category and procedure type.
Information on MBS item changes can be found at MBS Online.